NCT06698016View on ClinicalTrials.gov

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions

Healthy

Interventions

DRUG

Nemtabrutinib

Oral administration

DRUG

Efavirenz

Oral administration

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc. (Site 0001), Overland Park

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY